PML is a rare but serious infection of the central nervous system (CNS). The Progressive Multifocal Leukoencephalopathy (PML) Consortium is a joint effort between Pfizer, MedImmune, Roche, and Bristol-Myers Squibb intended to find methods to enable prediction and prevention of PML associated with immunomodulatory and immunosuppressive treatments.
Recent Article Published The PML Consortium’s review article “Progressive Multifocal Leukoencephalopathy: Current Treatment Options and Future Perspectives”, authored by members of the PML Consortium Clinical and Research Working Groups, has been published in Therapeutic Advances in Neurological Disorders. The full article can be accessed here.
2015 Conference Proceedings Coming Soon Proceedings of the August 2015 research conference will be published in October. Recordings of the conference will be made available on the Consortium's website.